Gilead Sciences Gets Initial OK On $247M HIV Antitrust Deal
By Bonnie Eslinger · September 21, 2023, 9:34 PM EDT
A California federal judge on Thursday granted preliminary approval to Gilead's deal to pay the direct purchasers of its HIV medications $246.8 million to end claims the pharmaceutical company cut a...
To view the full article, register now.